98%
921
2 minutes
20
The pentavalent is a vaccine against Diphtheria, Pertussis, Tetanus, Hepatitis B, and Haemophilus type B influenza. A child is considered a pentavalent vaccination dropout if they have received the first dosage as advised but have not obtained the third dose. In Tanzania, the first-dose receiver of pentavalent was approximately 97 %, whereas only 89 % received a third dose. Unfortunately, no studies have been done in Tanzania to evaluate the factors at the national level that are linked with first-versus third-dose pentavalent vaccine dropout; hence, we explored these factors here for the first time. A cross-sectional survey of randomly selected households was conducted. The sample size was calculated to provide overall, age- and sex-specific coverage estimates for measles-rubella vaccine evaluation among children aged between 9 and 59 months at the national level, as explained elsewhere. The fieldwork activities were done for one month from November to December 2019 for both Zanzibar and Tanzania Mainland. A total of 4460 caregivers of children aged 12-23 months were interviewed for routine immunization services, and a total of 4403 caregivers were included in this analysis of the uptake of the pentavalent vaccine. The number of children who received the first dose of the pentavalent vaccine was 4020 (91.5 %), while the number of children who received the third dose of the pentavalent vaccine was 3915 (89.4 %). The overall pentavalent vaccination dropout rate was 2.3 %. The rate was lower in Zanzibar (0.9 %) than in the Tanzanian mainland (2.4 %). Wealth quintile, sex of caregivers, and education were factors significantly associated with the pentavalent-3 dropout rate among children aged 12-23 months in Tanzania. Our results provide strong support for further efforts to improve current vaccination coverage to optimize the use of prioritized, timely, and appropriate interventions at the regional and district levels and to improve the health education given to expectant women during their clinic visits so they may comprehend the value of routine immunization.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12132042 | PMC |
http://dx.doi.org/10.1016/j.vaccine.2025.126962 | DOI Listing |
Sci Adv
September 2025
The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Influenza A viruses remain a global health threat, yet no universal antibody therapy exists. Clinical programs have centered on neutralizing mAbs, only to be thwarted by strain specificity and rapid viral escape. We instead engineered three non-neutralizing IgG2a mAbs that target distinct, overlapping epitopes within the conserved N terminus of the M2 ectodomain (M2e).
View Article and Find Full Text PDFEmerg Microbes Infect
December 2025
School of Global Health, Chinese Centre for Tropical Diseases Research, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
There is no vaccine for severe malaria. STEVOR antigens on the surface of -infected red blood cells are implicated in severe malaria and are targeted by neutralizing antibodies, but their epitopes remain unknown. Using computational immunology, we identified highly immunogenic overlapping B- and T-cell epitopes (referred to as multiepitopes, 7-27 amino acids) in the semiconserved domain of four STEVORs linked with severe malaria and clinical immunity.
View Article and Find Full Text PDFFront Immunol
September 2025
Department of Pediatrics, Taichung Veterans General Hospital, Taichung, Taiwan.
Introduction: Human papillomavirus (HPV) infection has been implicated in autoimmune processes, yet concerns remain about the potential autoimmune risks of HPV vaccination. Juvenile idiopathic arthritis (JIA) is a chronic autoimmune condition that typically manifests in childhood. The relationship between HPV vaccination and the development of JIA remains uncertain.
View Article and Find Full Text PDFPLoS One
September 2025
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Background: Foreign-born children may face greater barriers to accessing routine immunizations in Canada or their country of birth, but provincial surveillance data on immigration status are lacking. Using our provincial immunization repository linked to administrative data, we assessed immunization coverage among immigrant and refugee children in Ontario, Canada, compared with Ontario-born children and identified factors associated with being up-to-date (UTD).
Methods: We conducted a retrospective cohort study of children entering school during the 2012/13-2014/15 school years.
J Oncol Pharm Pract
September 2025
Department of Research & Development, Squad Medicine and Research (SMR), Amadalavalasa, Andhra Pradesh, India.
Cancer vaccines represent a transformative shift in oncology, aiming to prevent malignancies or treat established cancers by training the immune system to recognize tumor-specific or tumor-associated antigens. This review explores the diverse platforms and mechanisms supporting cancer vaccines, ranging from prophylactic vaccines such as HPV and hepatitis B vaccines that have significantly reduced virus-related cancers to therapeutic vaccines like Sipuleucel-T and T-VEC that extend survival in prostate cancer and melanoma. Vaccine types are classified, and delivery platforms including mRNA, peptide, dendritic cell and viral vector-based approaches are examined alongside pivotal clinical trial outcomes.
View Article and Find Full Text PDF